Visit our booth at the 2024 RNS Conference. Learn about our commitment to #rheumatology and explore our pipeline! #RNS2024
About us
Committed to providing US health care professionals medical and scientific information about Novartis products and disease education. See our community guidelines: http://bit.ly/2JnT2CP. If you have a medical inquiry, please contact us via http://bit.ly/31YWY3F or call us at 1-844-NVSocial. Our posts are for US HCP audiences only. • Please be patient; sometimes responses take time. • Please do not include your personal information in your posts. • We will respond to your questions/comments M-F, 9a-5p EST (no holidays). • The purpose of our posts is to share disease state education and congress information. We reserve the right to hide or remove any post that mentions specific product(s) or treatment(s) as that is not the intent of our posts. • If needed, we’ll show you how to get us your contact and case info securely. • We reserve the right to engage with posts on a case-by-case basis; not all posts will be acknowledged or responded to. • Novartis Pharmaceuticals Corporation does not endorse and is not responsible for the content of third-party links we may share. • Replying to or mentioning users does not imply our endorsement.
- Website
-
https://medinfo.novartispharmaceuticals.com
External link for Novartis US Medical
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
AWIR 2024 is just around the corner. Come talk to us about our commitment to #rheumatology! We’ll be showcasing our pipeline at our booth. #AWIR2024
Join us at AWIR 2024!
web.cvent.com
-
Join us at the 2024 RNS Conference to explore our commitment to #rheumatology! We’ll be showcasing our pipeline at our booth. #RNS2024 https://lnkd.in/eyd5pppM
Join us at RNS 2024!
conference.rnsnurse.org
-
Read more about a monotherapy treatment option for patients with chronic myeloid leukemia in chronic phase with the T315l mutation. This is intended for US healthcare professionals. https://lnkd.in/eUV7r8C5
-
Stop by booth 840 at #ADA2024! We have educational information on 2 important #ASVCD risk factors, Lp(a) & LDL-C. Our virtual booth, CV Halls of Science and Innovation, has resources that may optimize clinician-patient discussions on risk and risk-lowering considerations. https://lnkd.in/e6CB7aDq
-
Did you know that Bruton's tyrosine kinase (BTK) signaling plays a role in chronic spontaneous urticaria (CSU) pathophysiology? BTK mediates mast cell activation, degranulation, and release of inflammatory mediators, which may lead to the symptoms of #CSU such as itch, wheals, and angioedema. This mast cell activation occurs through crosslinking of immunoglobulin (Ig)E by autoallergens or IgG, or crosslinking of high-affinity IgE receptor by IgG. To learn more, explore CSU resources for HCPs on our website. #dermatology #allergy
HCPs: Visit our website to learn more about CSU pathophysiology
dermallergy.com
-
Learn about updated data on CAR-T therapy for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic #leukemia (B-ALL) by joining us at #ASCO24 on June 3 from 11:30 AM to 2:30 PM CT. View the data: https://lnkd.in/eMV85jzB
-
We had a great time at 2024 CMSC Annual Meeting! We are grateful for the opportunities to engage with HCPs who manage patients with #MultipleSclerosis, share insights, and explore collaborations. #CMSC2024 #Neurology
HCPs: Check out our website with tools and resources for managing MS
mshcpeducation.com
-
Visit us at #ASCO24 on June 2 at 4:30 to 6:00 PM CT to learn more from Dr Chia about the emerging role of ctDNA in HR+/HER2- advanced breast cancer. https://lnkd.in/gBGgkx3g
-
Visit us at #ASCO24 on June 1 from 3 to 6 PM CT to discover health-related quality of life and pain data for patients with metastatic castration-resistant #ProstateCancer (#mCRPC). Read the data: https://lnkd.in/em_Vv5D3